Pathophysiological factors in the development of diabetic nephropathy - New Insights;Patofiziološki čimbenici razvoja dijabetičke nefropatije - Nove Spoznaje

Acta Medica Croatica

Volumn 68, Issue 2, 2014, Pages 135-140

  Blaslov, Kristina ^a   Bulum, Tomislav ^a   Duvnjak, Lea ^a  

^a University of Zagreb   (Croatia)

Author keywords

BMP7; Diabetic nephropathy; FGF21; FGF23

Indexed keywords

ALBUMIN; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR 23; OSTEOGENIC PROTEIN 1; ENDOTHELIAL CELL GROWTH FACTOR;

ARTICLE; DIABETIC NEPHROPATHY; DISEASE COURSE; DYSLIPIDEMIA; EXCRETION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; RISK FACTOR; COMORBIDITY; CROATIA; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; EPIDEMIOLOGY; MALE;

CAUSALITY; COMORBIDITY; CROATIA; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ENDOTHELIAL GROWTH FACTORS; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; MALE; RISK FACTORS;

EID: 84931075297     PISSN: 13300164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. U.S. Renal Data System, USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2012.
2. Reutens AT. Epidemiology of diabetic kidney disease. Med Clin North Am 2013; 97: 1-18.
3. Metelko Ž, Pavlić Renar I, Poljičanin T, Szirovitza L, Turek S. Prevalence of diabetes mellitus in Croatia. Diabetes Research and Clinical Practice 2008; 81: 263-7.
4. IDF Atlas. 4th ed. Brussels: International Diabetes Federation; 2009 Dostupno na: http://www.diabetesatlas.org
5. Izvjesce za 2010. Zagreb: Nacionalni registar osoba sa šećernom bolescu CroDiab, 2011.
6. Poljičanin T., Šekerija M, Metelko Ž. Šećerna bolest-epide-miološko stanje i javnozdravstvene aktivnosti u Hrvatskoj. Hrvatski časopis za javno zdravstvo, 2011; 7: br 28.
7. Trošak dijabetesa u Hrvatskoj. Zagreb: Hrvatsko društvo za farmakoekonomiku i ekonomiku zdravsta, Naručitelj studije: NovoNordisk Hrvatska doo.
8. Adler AI, Stevens RJ, Manley S.E., Bilous RW, Cull CA, Holman RR; UKPDS GROUP. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003; 63: 225-32.
9. Dronavalli S, Duka I, Bakris GL The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab 2008; 4: 444-52.
10. Kramer CK, Leitão CB, Pinto L.C., Silveiro SP, Gross JL, Canani LH. Clinical and laboratory profile of patients with type 2 diabetes with low glomerular filtration rate and normoalbuminuria. Diabetes Care 2007; 30: 1998-2000.
11. Mogensen CE. Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia 1999; 42: 263-85.
12. Vujčić B, Turk T, Crnčević-Orlić Ž. Dijabetička nefropatija. Medicina fluminesis 2010; 46: 360-75.
13. Forbes JM, Cooper ME, Oldfield M.D., Thomas MC Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol 2003; 14(8 Suppl 3): S254-8.
14. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998; 352: 213-19.
15. Gall MA, Hougaard P, Borch-Johnsen K, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ 1997; 314: 783-8.
16. Ravid M, Brosh D, Ravid-Safran D, Levy Z., Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 1998; 158: 998-1004.
17. Smulders YM, Rakic M, Stehouwer C.D., Weijers RN, Slaats EH, Silberbusch J. Determinants of progression of microalbuminuria in patients with NIDDMA prospective study. Diabetes Care 1997; 20: 999-1005.
18. Stratton IM, Adler AI, Neil HA i sur. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321: 405-12.
19. Bulum T, Kolarić B, Duvnjak L. Lower levels of total HDL and HDL3 cholesterol are associated with albuminuria in normo-albuminuric type 1 diabetic patients. J Endocrinol Invest. 2013 Feb 12. [Epub ahead of print]
20. Brosius FC 3rd. New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy. Rev Endocr Metab Disord 2008; 9: 245-54.
21. Massagué J. The transforming growth factor-beta family. Annu Rev Cell Biol 1990; 6: 597-641.
22. Flanders K, Burmester J, Medical Applications of Transforming Growth Factor-β. Clin Med Res 2003; 1: 13-20.
23. Blobe GC, Schiemann WP, Lodish HF Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342: 1350-8.
24. Lupia E, Elliot SJ, Lenz O. IGF-1 decreases collagen degradation in diabetic NOD mesangial cells: implications for diabetic nephropathy. Diabetes 1999; 48: 1638-44.
25. Hirschberg R, Kopple JD The growth hormone insulin like growth factor 1 axis and renal glomerulal hyperfiltration. J Am Soc Nephrol 1992; 2: 1417-22.
26. Wetzel P, Haag J, Câmpean V i sur. Bone morphogenetic protein-7 expression and activity in the human adult normal kidney is predominantly localized to the distal nephron. Kidney Int 2006; 70: 717-23.
27. Ducy P, Karsenty G. The family of bone morphogenetic proteins. Kidney Int 2000; 57: 2207-14.
28. Zeisberg M. Bone morphogenic protein-7 and the kidney: current concepts and open questions. Nephrol Dial Transplant 2006; 21: 568-73. Epub 2005 Dec 22.
29. De Petris L., Hruska KA, Chiechio S, Liapis H. Bone morphogenetic protein-7 delays podocyte injury due to high glucose. Nephrol Dial Transplant 2007; 22: 3442-50.
30. Mitu GM, Wang SN, Hirschberg RR BMP7 is a podocyte survival factor and rescues podocytes from diabetic injury. Am J Physiol Renal Physiol 2007; 293: F1641-F8.
31. Hall PM. Prevention of progression in diabetic nephropathy. Postgraduate Med J 2004; 80: 624-33.
32. Wang SN, Lapage J, Hirschberg R. Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy. J Am Soc Nephrol 2001; 12: 2392-9.
33. Hefini S, Kamel A, El-Banaway H, Refai W., Khalil G. The role of BMP-7 and TGF-β1 in Diabetic Nephropathy. JMRI 2007; 28: 235-43.
34. Saito H, Kusano K, Kinosaki M i sur. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha, 25-dihydroxyvitamin D3 production. J Biol Chem 2003; 278: 2206-11.
35. Imanishi Y, Inaba M, Nakatsuka K i sur. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 2004; 65: 1943-6.
36. Titan SM, Zatz R, Graciolli FG FGF-23 as a predictor of renal outcome in diabetic nephropathy. Clin J Am Soc Nephrol 2011; 6: 241-7.
37. Winther K, Nybo M, Vind B., Pedersen SM, Højlund K, Rasmussen LM. Acute hyperinsulinemia is followed by increased serum concentrations of fibroblast growth factor 23 in type 2 diabetes patients. Scand J Clin Lab Invest 2012; 72: 108-13.
38. Kidney Disease Outcomes Quality Initiative (K/DOQI) (2004). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43(Suppl 1): S1-S290.
39. Mirza MA, Larsson A, Lind L., Larsson TE. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009; 205: 385-90.
40. Mirza MA, Hansen T, Johansson L i sur. Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol Dial Transplant 2009; 24: 3125-31.
41. Lin Z, Wu Z, Yin X i sur. Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS ONE 2010 5: e15534.
42. Han SH, Choi SH, Cho BJ i sur. Serum fibroblast growth factor-21 concentration is associated with residual renal function and insulin resistance in end-stage renal disease patients receiving long-term peritoneal dialysis. Metabolism: Clinical and Experimental 2010; 59: 1656-62.
43. Bulum T, Duvnjak L, Prkacin I. Estimated glucose disposal rate in assessment of renal function in patients with type 1 diabetes. Coll Antropol 2012; 36: 459-65.